Hsbc Holdings PLC Adc Therapeutics Sa Transaction History
Hsbc Holdings PLC
- $176 Billion
- Q3 2025
A detailed history of Hsbc Holdings PLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Hsbc Holdings PLC holds 10,521 shares of ADCT stock, worth $41,663. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,521Holding current value
$41,663% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ADCT
# of Institutions
103Shares Held
64.4MCall Options Held
77.8KPut Options Held
67.6K-
Redmile Group, LLC San Francisco, CA15.7MShares$62 Million6.9% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.14MShares$32.2 Million0.06% of portfolio
-
Prosight Management, LP Dallas, TX7.47MShares$29.6 Million7.9% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.91MShares$23.4 Million0.81% of portfolio
-
Morgan Stanley New York, NY3.67MShares$14.5 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $307M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...